Avidity Partners Management LP is required to file a 13D/G report to the SEC when the ownership of a company's total stock issue exceeds 5%.
Filed | Shares | Percentage | |
---|---|---|---|
Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
ONCOSEC MEDICAL Inc | February 14, 2022 | 2,945,000 | 7.5% |
SeaSpine Holdings Corp | February 14, 2022 | 2,010,000 | 5.5% |
Kadmon Holdings, Inc. | February 16, 2021 | 9,570,000 | 5.6% |
SUNESIS PHARMACEUTICALS INC | March 12, 2020 | 4,951,925 | 4.4% |